CL2017002803A1 - Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas - Google Patents

Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas

Info

Publication number
CL2017002803A1
CL2017002803A1 CL2017002803A CL2017002803A CL2017002803A1 CL 2017002803 A1 CL2017002803 A1 CL 2017002803A1 CL 2017002803 A CL2017002803 A CL 2017002803A CL 2017002803 A CL2017002803 A CL 2017002803A CL 2017002803 A1 CL2017002803 A1 CL 2017002803A1
Authority
CL
Chile
Prior art keywords
bacterial infections
heterocyclic compounds
prevention
treatment
compounds
Prior art date
Application number
CL2017002803A
Other languages
English (en)
Inventor
Julien Barbion
Audrey Caravano
Sophie Chasset
Francis Chevreuil
Nicolas Lecointe
Benoit Ledoussal
Strat Frédéric Le
Sébastien Richard
Christophe Simon
Sophie Vomscheid
Julie Brias
Sophia Briet
Fabien Faivre
Fralliec Géraldine Le
Chrystelle Oliveira
Original Assignee
Mutabilis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15305701.3A external-priority patent/EP3091018A1/en
Application filed by Mutabilis filed Critical Mutabilis
Publication of CL2017002803A1 publication Critical patent/CL2017002803A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS HETEROCÍCLICOS, SU PROCEDIMIENTO DE PREPARACIÓN, COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN ESTOS COMPUESTOS Y EL USO DE LAS MISMAS, OPCIONALMENTE EN COMBINACIÓN CON OTROS AGENTES ANTIBACTERIANOS Y/O COMPUESTOS BETA-LACTÁMICOS, PARA LA PREVENCIÓN O TRATAMIENTO DE LAS INFECCIONES BACTERIANAS. LA PRESENTE INVENCIÓN TAMBIÉN SE REFIERE AL USO DE ESTOS COMPUESTOS COMO INHIBIDORES DE Β-LACTAMASA Y/O COMO AGENTES ANTIBACTERIANOS.</p>
CL2017002803A 2015-05-07 2017-11-06 Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas CL2017002803A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305701.3A EP3091018A1 (en) 2015-05-07 2015-05-07 Heterocyclic compounds and their use in preventing or treating bacterial infections
EP16305144 2016-02-08

Publications (1)

Publication Number Publication Date
CL2017002803A1 true CL2017002803A1 (es) 2018-05-11

Family

ID=56083989

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002803A CL2017002803A1 (es) 2015-05-07 2017-11-06 Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas

Country Status (13)

Country Link
US (1) US10183943B2 (es)
EP (1) EP3292125B1 (es)
JP (1) JP6767392B2 (es)
KR (1) KR102713561B1 (es)
CN (1) CN107580595B (es)
AU (1) AU2016257338B2 (es)
BR (1) BR112017023359A2 (es)
CA (1) CA2983674A1 (es)
CL (1) CL2017002803A1 (es)
MX (1) MX2017014080A (es)
RU (1) RU2741496C2 (es)
TW (1) TWI754613B (es)
WO (1) WO2016177862A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170014135A1 (en) 2015-07-14 2017-01-19 Keith Edward Martin Surgical tool
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3300736B1 (en) * 2016-09-30 2021-05-05 Mutabilis Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections
EP3357924A1 (en) 2017-02-06 2018-08-08 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
KR102790878B1 (ko) 2018-08-09 2025-04-02 앤타바이오 에스에이에스 세린 베타-락타마제의 억제제로서 다이아자바이사이클로옥타논

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
MY162532A (en) * 2008-01-18 2017-06-15 Merck Sharp & Dohme Beta-lactamase inhibitors
KR101618424B1 (ko) * 2011-08-30 2016-05-04 욱크하르트 리미티드 1,6-디아자비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
KR20140144254A (ko) * 2012-03-30 2014-12-18 큐비스트 파마슈티컬즈 인코포레이티드 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 β-락타마제 억제제
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9487474B2 (en) 2012-06-04 2016-11-08 Elkimia, Inc. Imino compounds as protecting agents against ultraviolet radiations
US20140315876A1 (en) * 2013-03-15 2014-10-23 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
NZ719215A (en) * 2013-10-22 2020-04-24 Wockhardt Ltd Pharmaceutical compositions comprising antibacterial agents
WO2016156348A1 (en) * 2015-03-31 2016-10-06 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections

Also Published As

Publication number Publication date
KR20180002650A (ko) 2018-01-08
RU2017135321A (ru) 2019-04-10
TWI754613B (zh) 2022-02-11
RU2741496C2 (ru) 2021-01-26
RU2017135321A3 (es) 2019-08-13
EP3292125B1 (en) 2019-09-04
MX2017014080A (es) 2018-07-06
US20180093985A1 (en) 2018-04-05
TW201643165A (zh) 2016-12-16
KR102713561B1 (ko) 2024-10-08
CN107580595B (zh) 2020-09-18
CA2983674A1 (en) 2016-11-10
WO2016177862A1 (en) 2016-11-10
EP3292125A1 (en) 2018-03-14
US10183943B2 (en) 2019-01-22
BR112017023359A2 (pt) 2018-07-17
NZ736152A (en) 2024-09-27
AU2016257338B2 (en) 2020-03-05
JP2018515504A (ja) 2018-06-14
JP6767392B2 (ja) 2020-10-14
CN107580595A (zh) 2018-01-12
AU2016257338A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
CL2017002482A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
CL2017003142A1 (es) Composiciones que comprenden cepas bacterianas
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2017002650A1 (es) Compuestos novedosos
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
PE20180243A1 (es) Composiciones que comprenden cepas bacterianas
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX381488B (es) Indoles para su uso en la infección por el virus de la gripe.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
CR20160433A (es) Nuevos compuestos
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
EA201892822A1 (ru) Новые антибактериальные соединения
CL2016000568A1 (es) Compuestos derivados de 2h-indazol-2-il-n-hidroxi-2-metilsulfonil-2-metil-butanamida sustituidos o sus sales; sus composiciones farmacéuticas que los contiene y su uso para la prevención y/o tratamiento de infecciones bacterianas gram-negativas.
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
BR112016022722A2 (pt) pró-fármacos de inibidores da transcriptase reversa de hiv